Cibus Inc Ordinary Shares - Class A CBUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cibus to Participate in the Food+ Forum during the 79th Session of the United Nations General Assembly
-
Cibus Announces Pricing of Public Offering of Class A Common Stock
-
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
-
Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
-
Sidoti Events, LLC's Virtual August Micro-Cap Conference
-
Cibus to Participate in Upcoming August Investor Events
-
Cibus Reports Second Quarter Financial Results and Provides First Half Business Update
-
Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
Trading Information
- Previous Close Price
- $3.35
- Day Range
- $3.09–3.42
- 52-Week Range
- $3.09–23.18
- Bid/Ask
- $3.13 / $3.45
- Market Cap
- $85.99 Mil
- Volume/Avg
- 252,899 / 192,654
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 183
- Website
- https://www.cibus.com
Comparables
Valuation
|
Metric
|
CBUS
|
JSPR
|
NGNE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.28 | 2.83 | 3.52 |
Price/Sales | 13.31 | — | 561.60 |
Price/Cash Flow | — | — | — |
Price/Earnings
CBUS
JSPR
NGNE
Financial Strength
|
Metric
|
CBUS
|
JSPR
|
NGNE
|
|---|---|---|---|
Quick Ratio | 1.07 | 10.63 | 11.82 |
Current Ratio | 1.14 | 10.79 | 12.17 |
Interest Coverage | −10.03 | — | −3,812.79 |
Quick Ratio
CBUS
JSPR
NGNE
Profitability
|
Metric
|
CBUS
|
JSPR
|
NGNE
|
|---|---|---|---|
Return on Assets (Normalized) | −16.27% | −50.56% | −35.03% |
Return on Equity (Normalized) | −29.46% | −58.00% | −69.86% |
Return on Invested Capital (Normalized) | −17.21% | −61.81% | −66.47% |
Return on Assets
CBUS
JSPR
NGNE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cqtvcvczrt | Xsclq | $524.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tvzwdpgt | Bqwxy | $120.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gxycwbpq | Nfmkxfn | $115.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bcsqqff | Btdrk | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Xqhpfkd | Vszs | $32.4 Bil | |||
| BioNTech SE ADR
BNTX
| Rspkxdcnr | Xqcvy | $28.2 Bil | |||
| Moderna Inc
MRNA
| Qtlfzsyz | Hkxmj | $25.7 Bil | |||
| United Therapeutics Corp
UTHR
| Pfmtwpkxl | Dxbd | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lhzjstpqq | Mgcklf | $13.4 Bil | |||
| Incyte Corp
INCY
| Ftmywstb | Wqfbf | $12.7 Bil |
United States